# EU-1-14-974_public-assessment-report_20150213_20150213_cerdelga-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES
HEALTH
20 November 2014
EMA/57549/2015
Committee for Medicinal Products for Human Use (CHMP)
Cerdelga
(eliglustat)
Procedure No. EMEA/H/C/003724
Applicant: Genzyme Europe BV
Assessment report for an initial marketing authorisation application
Assessment report as adopted by the CHMP with
all commercially confidential information deleted
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
7
1.1. Submission of the dossier
7
1.2. Manufacturers
8
1.3. Steps taken for the assessment of the product
8
2. Scientific discussion
9
2.1. Introduction
9
2.2. Quality aspects
11
2.2.1. Introduction
11
2.2.2. Active Substance.
11
2.2.3. Finished Medicinal Product.
13
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
15
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
15
2.2.6. Recommendation(s) for future quality development.
15
2.3. Non-clinical aspects
16
2.3.1. Introduction
16
2.3.2. Pharmacology
16
2.3.3. Pharmacokinetics
18
2.3.4. Toxicology
19
2.3.5. Ecotoxicity/environmental risk assessment
21
2.3.6. Discussion on non-clinical aspects
22
2.3.7. Conclusion on the non-clinical aspects
24
2.4. Clinical aspects
24
2.4.1. Introduction
24
2.4.2. Pharmacokinetics
28
2.4.3. Pharmacodynamics.
31
2.4.4. Discussion on clinical pharmacology
32
2.4.5. Conclusions on clinical pharmacology.
33
2.5. Clinical efficacy
33
2.5.1. Dose response studies
34
2.5.2. Main studies
34
2.5.3. Discussion on clinical efficacy.
54
2.5.4. Conclusions on the clinical efficacy
58
2.6. Clinical safety
59
2.6.1. Discussion on clinical safety
62
2.6.2. Conclusions on the clinical safety
62
2.7. Pharmacovigilance
63
2.8. Risk Management Plan
63
2.9. Product information.
68
2.9.1. User consultation
68
3. Benefit-Risk Balance
69
4. Recommendations
73
Cerdelga
EMA/68065/2015
Page 2/75
